Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

Civacir® (Civacir) - Prophylaxis hepatitis C reinfection
Tregalizumab (BT-061) - other diseases
IgM Concentrate (BT-086) - Severe community acquired pneumonia
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors
(BT-063) - Systemic lupus erythematosus
Fibrinogen (BT-524) - Congenital fibrinogen deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Release according to Article 26, Section 1 of the WpHG ...

24.05.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Publication of the offer document on the voluntary publ...

18.05.2017, News

Publication of the offer document on the voluntary public tender for Biotest AG by CREAT Group - Offer document reaffirms the offer announced on April 7, 2017 - The Management Board and the ... [More]

DGAP-AFR: Biotest AG: Preliminary announcement of the p...

17.05.2017, AFR

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Financial report (half-year/Q2) Date of disclosure / German: August 14, 2017 Date of disclosure / ... [More]

Biotest AG opens seventh plasma collection centre in Hu...

16.05.2017, News

Biotest AG opens seventh plasma collection centre in Hungary - 15 plasma collection centres in Europe and - 22 in the US to ensure long-term plasma supply Dreieich, 16 May 2017. Biotest ... [More]

Biotest reports revenue of EUR 110 million in the first...

10.05.2017, News

Biotest reports revenues of EUR 110.5 million in the first quarter 2017 Dreieich, 10 May 2017. In the first quarter of 2017, the Biotest Group generated sales of EUR 110.5 million, after EUR 133.6 ... [More]

Correction of a release from 07.04.2017, 15:23 CET/CEST...

04.05.2017, PVR

Correction of a notification of Major Holding published on 07.04.2017 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for ... [More]

Release according to Article 26, Section 1 of the WpHG ...

28.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Voluntary recall of human albumin

26.04.2017, News

Biotest: Voluntary recall of human albumin - Already quarantined batches of human albumin are recalled - Consequences of the one-time effect on Sales and EBIT are currently being evaluated - As ... [More]

Biotest recalls human albumin and reduces forecast

26.04.2017, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest recalls human albumin and reduces forecast Dreieich, 26 April 2017. In close co-operation with regulatory ... [More]

Biotest AG opens sixth plasma collection centre in Hung...

19.04.2017, News

Biotest AG opens sixth plasma collection centre in Hungary - 14 plasma collection centres in Europe and - 22 in the US to ensure long-term plasma supply Dreieich, 19 April 2017. Biotest ... [More]

Biotest informs about limited availability of albumin

13.04.2017, News

Biotest informs about limited availability of albumin - Due to an equipment failure the availability of albumin is currently limited - Consequences on sales and annual results are currently not ... [More]

Release according to Article 26, Section 1 of the WpHG ...

13.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Release according to Article 26, Section 1 of the WpHG ...

11.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Correction of a release from 06.04.2017, 14:54 CET/CEST...

11.04.2017, PVR

Announcement JO HAMBRO Capital Management Limited informed us that they retract their notification published by us on 6h April 2017, as no thresholds had been crossed which are relevant for ... [More]

Release according to Article 26, Section 1 of the WpHG ...

07.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification Acquisition/disposal of ... [More]

Biotest AG and Creat enter into Business Combination Ag...

07.04.2017, News

Biotest AG and Creat enter into Business Combination Agreement - Chinese strategic investor Creat to make a voluntary public takeover offer - Shareholders will be offered EUR 28.50 in cash per ... [More]

Takeover Offer: Chinese strategic investor Creat to mak...

07.04.2017, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Takeover Offer: Chinese strategic investor Creat to make a voluntary public takeover offer for the shares of Biotest AG ... [More]

Release according to Article 26, Section 1 of the WpHG ...

06.04.2017, PVR

Notification of Major Holdings 1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of ... [More]

Discussions regarding business combination

29.03.2017, Adhoc

Announcement according to Article 17 European Market Abuse Regulation (MAR) Discussions regarding business combination Dreieich, 29 March 2017. Biotest Aktiengesellschaft and Creat Group ... [More]

Discussions regarding possible business combination

29.03.2017, News

Discussions regarding possible business combination Dreieich, 29 March 2017. Biotest AG announced today that it is in discussion with Creat Group Corporation (Creat), a leading Chinese investment ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Letter to shareholders

preview

Letter to shareholders - 4.11.2015
PDF, 162 KB
[ Download ]